Abstract
The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Current Pharmaceutical Design
Title: The Urokinase Receptor in Hematopoietic Stem Cells Mobilization
Volume: 17 Issue: 19
Author(s): Francesco Blasi
Affiliation:
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Abstract: The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Export Options
About this article
Cite this article as:
Blasi Francesco, The Urokinase Receptor in Hematopoietic Stem Cells Mobilization, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718206
DOI https://dx.doi.org/10.2174/138161211796718206 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole: Synthesis, Docking Studies and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Drug Delivery Letters The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Genes Involved in Hereditary Hearing Impairment
Current Genomics Prospects of Utilizing Computational Techniques for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews Network of WNT and Other Regulatory Signaling Cascades in Pluripotent Stem Cells and Cancer Stem Cells
Current Pharmaceutical Biotechnology Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Synthesis and Biological Evaluation of New 4-Thiazolidinone Derivatives as Carbonic Anhydrase Inhibitors
Letters in Organic Chemistry Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets